先为达生物先颐达®获批 用于成人2型糖尿病血糖控制

Core Insights - Xianweida Biotech has received approval from the National Medical Products Administration (NMPA) for its drug, Xianyida® (Enogratide injection), aimed at blood sugar control in adults with type 2 diabetes [1][2] - The number of diabetes patients in China is projected to reach approximately 148 million by 2024, indicating a growing market for diabetes treatments [1] - The treatment paradigm for diabetes is evolving from mere blood sugar control to a comprehensive approach that includes reducing cardiovascular risks and protecting organ function [1] Company Highlights - Enogratide injection is a cAMP-biased GLP-1 receptor agonist, which differs from non-biased GLP-1 receptor agonists by preferentially activating the cAMP signaling pathway while minimizing β-arrestin recruitment [1] - This unique mechanism is key to enhancing clinical efficacy and improving metabolic benefits, marking a new direction in precision treatment for diabetes [1] - The approval is based on two pivotal Phase III clinical studies demonstrating the efficacy and safety of Enogratide injection in Chinese adults with type 2 diabetes, showing comprehensive benefits in glycemic control, weight reduction, and metabolic improvement over 52 weeks [2] Industry Context - The 2024 edition of the "Chinese Diabetes Prevention and Treatment Guidelines" has recognized the significance of GLP-1 receptor agonists, including Enogratide, in diabetes management [1] - The approval of Enogratide is seen as a significant milestone for Chinese pharmaceutical companies in the field of metabolic diseases, highlighting the potential for innovation in diabetes treatment [2] - The company aims to leverage this approval to further its commitment to technological innovation and expedite the availability of transformative therapies for millions of patients [2]